We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
- Authors
Hochhaus, A; Baccarani, M; Deininger, M; Apperley, J F; Lipton, J H; Goldberg, S L; Corm, S; Shah, N P; Cervantes, F; Silver, R T; Niederwieser, D; Stone, R M; Dombret, H; Larson, R A; Roy, L; Hughes, T; Müller, M C; Ezzeddine, R; Countouriotis, A M; Kantarjian, H M
- Abstract
Dasatinib, a potent inhibitor of BCR-ABL in vitro, is effective for patients with chronic myelogenous leukemia (CML) resistant or intolerant to imatinib. To provide a more definitive assessment of dasatinib in chronic-phase (CP)-CML, we report extended follow-up of a phase II trial, presenting data for the entire patient cohort (N=387). Dasatinib (70 mg) twice daily was administered to patients with imatinib-resistant or -intolerant CP-CML. With median follow-up of 15.2 months (treatment duration, <1-18.4 months), a complete hematologic response was attained or maintained in 91% of patients. A major cytogenetic response (MCyR) was attained or maintained by 59% (52% imatinib resistant and 80% imatinib intolerant); this was complete in 49% of patients (40% imatinib resistant and 75% imatinib intolerant). Of 230 patients achieving an MCyR, 7 experienced disease progression. Fifteen-month progression-free survival was 90% while overall survival was 96%. Grade 3/4 thrombocytopenia and neutropenia were reported in 48 and 49% of patients, respectively. Non-hematologic toxicity (any grade) consisted primarily of diarrhea (37%), headache (32%), fatigue (31%), dyspnea (30%) and pleural effusion (27%). Pleural effusions were classified as grade 3 in 6% of reported events, with no incidence of grade 4. Dasatinib is associated with high response rates in patients with imatinib-resistant or -intolerant CP-CML.
- Publication
Leukemia, 2008, Vol 22, Issue 6, p1200
- ISSN
1476-5551
- Publication type
Journal Article
- DOI
10.1038/leu.2008.84